Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in EGFR-mutant NSCLC after Osimertinib
NCT04099836Phase 2Terminated
- Sponsor
- Duke University
- Start
- Jul 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Duke University. Started Jul 2020; status: terminated.
02
Drugs
atezolizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04099836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099836.